PMID- 30122243
OWN - NLM
STAT- MEDLINE
DCOM- 20181029
LR  - 20190701
IS  - 2213-3763 (Electronic)
IS  - 0019-4832 (Print)
IS  - 0019-4832 (Linking)
VI  - 70 Suppl 1
IP  - Suppl 1
DP  - 2018 Jul
TI  - Prognostic value of soluble ST2 biomarker in heart failure patients with reduced 
      ejection fraction - A multicenter study.
PG  - S79-S84
LID - S0019-4832(17)30337-1 [pii]
LID - 10.1016/j.ihj.2017.09.010 [doi]
AB  - OBJECTIVE: To study the prognostic value of soluble Suppression of 
      Tumorigenicity-2 (sST2) in heart failure patients with reduced ejection fraction 
      (HFrEF). METHODS: In this prospective, observational, multicenter study, patients 
      with heart failure (HF) and left ventricular ejection fraction (LVEF) <50% were 
      included. Clinical evaluation and serum levels of sST2 were estimated at five 
      time points during follow up. Study endpoint was the relationship of baseline and 
      serial sST2 concentration in the blood to the composite endpoints of cardiac 
      death and re-hospitalization for worsening of HF during one year follow up 
      period. RESULTS: A total of 141 patients were enrolled. The mean age was 
      60+/-10.4years. At baseline evaluation, 49.6% patients were in New York Heart 
      Association (NYHA) class III and 36.2% in class IV. Adverse events were observed 
      in 57 patients (40.4%); 25 (17.7%) were re-hospitalized due to worsening of HF 
      and 32 (22.7%) died due to cardiac causes. The median value of baseline sST2 was 
      46.36ng/ml (IQR 31.30-78.38). sST2 concentration at baseline was significantly 
      higher among patients with adverse events in comparison to patients without 
      adverse events (p=<0.001). Receiver operating characteristic curve (ROC) for 
      baseline sST2 concentration identified 49ng/ml as optimal cut-off value to 
      predict cardiac death and re-hospitalization, with a sensitivity and specificity 
      of 72% and 75%, respectively. CONCLUSION: In patients with HFrEF, sST2 
      concentration at baseline as well as on serial testing was significantly 
      correlated with cardiac death and re-hospitalization for worsening of HF.
CI  - Copyright (c) 2017. Published by Elsevier B.V.
FAU - Bahuleyan, C G
AU  - Bahuleyan CG
AD  - Cardiovascular Centre, Ananthapuri Hospitals and Research Institute, 
      Thiruvananthapuram, Kerala, India. Electronic address: bahuleyan2001@yahoo.co.uk.
FAU - Alummoottil, George Koshy
AU  - Alummoottil GK
AD  - Department of Cardiology, Government Medical College, Thiruvananthapuram, Kerala, 
      India.
FAU - Abdullakutty, Jabir
AU  - Abdullakutty J
AD  - Lisie Heart Institute, Kochi, Kerala, India.
FAU - Lordson, A Jinbert
AU  - Lordson AJ
AD  - Cardiovascular Centre, Ananthapuri Hospitals and Research Institute, 
      Thiruvananthapuram, Kerala, India; Global Institute of Public Health, Chacka, 
      Thiruvananthapuram, Kerala, India.
FAU - Babu, Shifas
AU  - Babu S
AD  - Cardiovascular Centre, Ananthapuri Hospitals and Research Institute, 
      Thiruvananthapuram, Kerala, India.
FAU - Krishnakumar, V V
AU  - Krishnakumar VV
AD  - Cardiovascular Centre, Ananthapuri Hospitals and Research Institute, 
      Thiruvananthapuram, Kerala, India.
FAU - Pillai, Anand M
AU  - Pillai AM
AD  - Cardiovascular Centre, Ananthapuri Hospitals and Research Institute, 
      Thiruvananthapuram, Kerala, India.
FAU - Abraham, George
AU  - Abraham G
AD  - Department of Laboratory Medicine, Ananthapuri Hospitals and Research Institute, 
      Thiruvananthapuram, Kerala, India.
FAU - Dilip, M N
AU  - Dilip MN
AD  - Department of Cardiology, Government Medical College, Thiruvananthapuram, Kerala, 
      India.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20170920
PL  - India
TA  - Indian Heart J
JT  - Indian heart journal
JID - 0374675
RN  - 0 (Biomarkers)
RN  - 0 (IL1RL1 protein, human)
RN  - 0 (Interleukin-1 Receptor-Like 1 Protein)
RN  - 0 (Receptors, Interleukin-1)
SB  - IM
MH  - Biomarkers/blood
MH  - Female
MH  - Heart Failure/*blood/physiopathology
MH  - Humans
MH  - Interleukin-1 Receptor-Like 1 Protein/*blood
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - ROC Curve
MH  - Receptors, Interleukin-1
MH  - Stroke Volume/*physiology
MH  - Ventricular Function, Left/*physiology
PMC - PMC6097172
OTO - NOTNLM
OT  - Biomarker
OT  - Heart failure
OT  - Prognosis
OT  - Serial testing
OT  - sST2
EDAT- 2018/08/21 06:00
MHDA- 2018/10/30 06:00
PMCR- 2019/07/01
CRDT- 2018/08/21 06:00
PHST- 2017/05/22 00:00 [received]
PHST- 2017/08/29 00:00 [revised]
PHST- 2017/09/15 00:00 [accepted]
PHST- 2018/08/21 06:00 [entrez]
PHST- 2018/08/21 06:00 [pubmed]
PHST- 2018/10/30 06:00 [medline]
PHST- 2019/07/01 00:00 [pmc-release]
AID - S0019-4832(17)30337-1 [pii]
AID - 10.1016/j.ihj.2017.09.010 [doi]
PST - ppublish
SO  - Indian Heart J. 2018 Jul;70 Suppl 1(Suppl 1):S79-S84. doi: 
      10.1016/j.ihj.2017.09.010. Epub 2017 Sep 20.